MedTrace Logo

Adverse Events and Genomics in Schizophrenia

NCT01966588 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2016-06-01

No results posted yet for this study

Summary

The purpose of this study is to find genes that predict whether or not a person will develop side effects to antipsychotic medications, such as weight gain, blood sugar dysregulation, or immune cell abnormalities. We will be collecting blood samples from participants who are taking second-generation antipsychotic medications. These blood samples will be stored over the long-term in a biobank, and will be used for later genetic testing and other cell-based studies.

Conditions

  • Adverse Effect of Other Antipsychotics and Neuroleptics

Interventions

OTHER

Blood samples for whole genomic/transcriptomic sequencing

Participants in the Metabolic Arm will receive one blood draw, while participants in the Neutropenia Arm will receive a total of three blood draws: one at baseline, another 3 months later, and one 1 year later, with the possibility of further follow-up.

OTHER

UKU Side Effect Rating Scale

Clinician-rated scale of psychic, neurological, autonomic, and other side effects related to psychotropic drugs; ratings are based on a 10-30 minute interview with each participant.

Sponsors & Collaborators

Principal Investigators

  • Alasdair M Barr, Ph.D. · The University of British Columbia

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01966588 on ClinicalTrials.gov